Dominion Energy Inc vs Twist Bioscience Corp — how do they compare? Dominion Energy Inc trades at $71.2 (market cap $62.27B), while Twist Bioscience Corp trades at $92.62 (market cap $5.63B). The key difference: Dominion Energy Inc is far larger — about 11.1× Twist Bioscience Corp's market cap, and Dominion Energy Inc pays a 3.77% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| D | TWST | |
|---|---|---|
Market Cap | $62.27B | $5.63B |
Sector | Utilities | Health |
52-Week High | $71.32 | $102.88 |
52-Week Low | $56.55 | $24.16 |
Enterprise Value | $114.67B | $5.55B |
Dividend Yield | 3.77% | — |
Signals from Pluang's Aura AI — not financial advice
Dominion Energy (D) trades at $70.8, up 1.03% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $70.14. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.95, and maintains a solid net income margin of 16.93%. Recent news highlights a proposed $66.8 billion acquisition by NextEra Energy, positioning D at the center of AI-driven power demand trends.
The outlook for D is mixed; upside potential exists from rising electricity demand and strategic acquisitions, but risks include regulatory scrutiny of the NextEra deal and high debt levels. Analysts are cautious, with 59% holding a neutral rating, reflecting balanced opportunities and headwinds for investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →